In Observance of U.S. Holiday, M.L.K. Day, Agilent Cross Lab/ iLab Operations Software Support Help Desk will be closed during U.S. hours on Monday January 18th, 2021. We will resume regular U.S. support hours on Tuesday January 19th, 2021. EU and APAC Support will remain open during this time. For urgent matters, please add "Urgent" to the ticket/ email subject or press "1", when prompted, to escalate a call on the iLab Support phone and we will prioritize those requests first.
In 2018-19, UT Southwestern embarked on an ambitious gene therapy program, the future of curative medicine, by establishing Viral Vector Core lab and GMP AAV Viral Vector production facility to serve its own clinical studies and the community at large. Through building a professional team of unique expertise and collaborative efforts with multiple stakeholders, our goal is to establish a highly efficient full-service viral vector production facility that can respond timely to provide AAV-based research reagents and services to investigators at UT Southwestern, as well as to facilitate translational research applying gene therapy approaches to treat genetic disease. The objective is to deliver the highest quality AAV vectors to our academic, government, foundation, and biotech industry clients.
Mission
Our primary mission is to serve the research community at UT Southwestern by providing AAV vectors and associated services for gene therapy translational studies. Through dedicated efforts of highly skilled professional investigators, collaborators and foundations, we will bring the future of gene-based medicine into the present.
Vision
To be a leading gene therapy program, locally, nationally and globally.
Team Values
Production Facility
The Translational Gene Therapy Core (TGTC) - previously known as Viral Vector Core - is located on the 4th floor of the Green Research Building (Building Y) on UT Southwestern’s south campus. The space includes separate suites for Process Development, Quality Control (Y4.206) and GMP AAV Viral Vector production facility (Y4.230).
Our Production Platform
Our production process utilizes triple-transfection of suspension HEK293 cells, using serum-free media. Our GMP production suite can utilize a 500 L bioreactor for a single production run. Downstream purification of AAV relies on filtration, concentration, and chromatography steps without the use of density gradients. We maintain consistency of our manufacturing process across all production scales (0.5 L to 500 L), to ensure comparability of the product throughout the translational pipeline.
Steven Gray, Ph.D. | Director, Translational Gene Therapy Core (TGTC)
steven.gray@utsouthwestern.edu
214-648-0670
Samer Dahshi, M.S. | TGTC - Operations Manager
samer.dahshi@utsouthwestern.edu
214-648-7164
Hours | Location |
Monday - Friday 8am - 5pm |
Y04.214 |
Name | Role | Phone | Location | |
---|---|---|---|---|
Steven Gray, Ph.D. |
Director,Translational Gene Therapy Core (TGTC)
|
214-648-0670
|
steven.gray@utsouthwestern.edu
|
NA02.508AA
|
Samer Dahshi, M.S. |
Operations Manager - TGTC
|
214-648-7164
|
samer.dahshi@utsouthwestern.edu
|
Y04.214
|